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exploited in magnetic hyperthermia therapy of cancer. In this contribution, we provide a critical review of the
use of MNPs andmagnetic hyperthermia as drug release and gene expression triggers for cancer therapy. Several
strategies for the release of chemotherapeutic drugs from thermo-responsive matrices are discussed, providing
representative examples of their application at different levels (from proof of concept to in vivo applications).
The potential of magnetic hyperthermia to promote in situ expression of therapeutic genes using vectors that
contain heat-responsive promoters is also reviewed in the context of cancer gene therapy.
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Magnetic nanoparticles (MNPs) emerged more than two decades
ago as promising tools for a wide array of biomedical applications [1].
Several magnetic materials have been studied although the most popu-
lar ones are iron oxides, due to their excellent biocompatibility proper-
ties. These materials have been approved by the Food and Drug
Administration (FDA) of the USA as magnetic resonance imaging
(MRI) contrast agents [2] and are being extensively investigated as
drug delivery agents using external magnetic fields [3] and as heat me-
diators for cancer treatment using alternatingmagneticfields (AMF) [4].
This last biomedical application is usually described as magnetic hyper-
thermia (MHT).
Magnetic hyperthermia is a promising therapy for the localized
treatment of cancer. Given that cancer cells are more sensitive to heat
than normal cells, MNPs are introduced in the tumour area and used
as heating agents to increase the local temperature to induce cell
death or alter the growth and differentiation of the cancer cells. The pro-
duction of energy in the form of heat is based on the reorientation of the
magnetic moments of theMNPs under exposure to an AMF [5]. In small
monodomain particles, this reorientation can occur by twomechanisms
[6]: Néel rotation, when the magnetic moment rotates overcoming the
anisotropy energy barrier [7], and Brown rotation, when thewhole par-
ticle rotates creating frictional losses with the environment [8].
Despite the immense amount of research being performed in this
area, cancer treatment by magnetic hyperthermia still faces many chal-
lenges until it can be adopted as a widely used approach [9]. Some
examples are the difficulties to achieve a uniform thermal profile within
the tumour [10], the lack of knowledge of the molecular mechanisms
involved in the cellular damage [11], the reticence from the medical
community and the difficulties to access the technical facilities needed
for the treatment [12].
Recently, new approaches based on the use of magnetic hyperther-
mia for cancer treatment that go one step further than traditional mag-
netic hyperthermia have been developed [13]. Instead of focusing just
on the heat generation to induce cell death, the main aim is to use the
temperature increase as a stimulus able to trigger the release or the ac-
tivation of therapeutic molecules.
The different stimuli that can be used for triggering on demand re-
lease of the drug/molecule of interest at the desired target site can be
classified in two major categories: internal and external [14]. Internal
stimuli approaches are based on the different physicochemical situa-
tions that can be present at the target site. Focusing on tumours, differ-
ences in the pH [15,16] and/or the overexpression of some enzymes
[17,18] can be used as internal stimuli to control the release of the con-
tent of the nanomaterial acting as carrier. Although this idea seems to be
promising there are difficulties for the design of an effective drug release
system. The differences in the pH or the enzyme concentration should
be large enough to avoid the premature release of the cargo in the
blood stream or in any other not desired environment. This problem
could be solved with the use of external stimuli, which can be switched
on to achieve the optimal spatio-temporal control of the drug release. In
addition to the alternating magnetic fields described above to release
energy from magnetic nanoparticles, other non-invasive external stim-
uli, such as light or ultrasounds, have been successfully used to promote
drug release fromnanoparticulate systems [19–21]. Absorbed lightwith
wavelengths ranging from the ultraviolet (UV) to the near infrared
(NIR) region of the spectrum can lead to the release of the drug from
the nanocarrier system by different mechanisms, includingPlease cite this article as: M. Moros, et al., Triggering antitumoural drug rel
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or production of singlet oxygen. However, ultraviolet-visible light suf-
fers from low penetration depth, although this aspect can be improved
by using near infrared (NIR)-responsive systems. Ultrasoundwaves can
also promote drug delivery from nanocarriers throughmechanical and/
or thermal effects. The use of high-intensity focused ultrasounds (HIFU)
for the release of chemotherapeutic drugs from thermosensitive carriers
(ThermoDox®) is currently under clinical investigation for the treat-
ment of liver tumours [22]. Nevertheless, the use of high-frequency ul-
trasounds that might be required to ensure high penetration depths
could lead to adverse effects such as thermal damage of the healthy tis-
sue [20].
There are several advantages related to theuse of external stimuli for
the release or activation of therapeutic agents. First, the therapeutic
molecules are protected frompremature degradation in the body before
reaching the targeted area. In this sense, a high stability (both physical
and chemical) of the polymers and liposomes generally used for these
approaches is of paramount importance. For this purpose, the composi-
tion of these nanostructures plays a key role in avoiding the passive per-
meation of the encapsulated or bound agents. Another advantage
associated to the use of external stimuli to release or activate therapeu-
tic agents is that it also allows the better control of the timing, meaning
that they are active at the desired time point.
The use of alternating magnetic fields as external stimuli presents
several additional advantages. First, using field gradients from MPI
(Magnetic Particle Imaging) equipment it is possible to have a careful
control of the spatial localization of the release of therapeuticmolecules,
which avoids problems related to side effects and systemic cytotoxicity
[23]. Besides, synergistic effects between hyperthermia and chemother-
apy have been described [24], as the temperature increase is able to
make the tumour cells more sensitive to some therapeutic molecules
[25,26].
Two main design strategies are being followed in the development
of heat-responsive nanostructures to trigger the release of antitumoural
agents mediated by magnetic hyperthermia. The first one is based on
the link or encapsulation of a drug in a thermo-responsive matrix that
will be transformed once the temperature is raised allowing the release
of the cargo. The second one relies on the expression of genes, using
vectors containing inducible promoters, such as heat-responsive ones.
The main idea behind the use of thermo-responsive matrices is that
the heat induced by the MNPs under the AMF is able to transform the
matrix in which the therapeutic agent is carried. Four major strategies
are being followed to this end (Fig. 1). The first one is the break or desta-
bilization of the bond between the therapeuticmolecule and thematrix,
allowing its release (Fig. 1A). The second strategywould take advantage
of the heat-induced transformation of the thermo-responsive matrix
(Fig. 1B), allowing the escape of the therapeutic drug from the matrix,
mainly based on the use of thermo-responsive polymers or
magnetoliposomes. A possible mechanism for this approach would be
related to the use of materials with a conformational transition temper-
ature above the body temperature. The third approach is based on the
use of a porous material, where the therapeutic agents are retained,
whose pores are blocked by a thermo-responsive material (Fig. 1C).
The application of heat induces a transformation on the pore coating
allowing the release of the therapeutic agents. This approach is usually
referred to as “switchable gates”. Finally, a fourth and less common
strategy consists in the degradation of the matrix, allowing the release
of its cargo, using thermo-sensitive polymers that undergo a dissolution
process at higher temperatures (Fig. 1D).ease and gene expression bymagnetic hyperthermia, Adv. Drug Deliv.
Fig. 1. Strategies for the release of therapeutic molecules (purple spheres) linked to a thermo-responsive matrix (green). A) Breaking the bond between the drug and the particle,
B) Transforming the matrix structure, C) Using the thermo-responsive matrix to open/close the pores from a mesoporous material and D) Degrading the matrix structure.
3M. Moros et al. / Advanced Drug Delivery Reviews xxx (xxxx) xxx–xxxInstead of carrying a drug to be locally released, an alternative strat-
egy aims at the in situ expression of a therapeutic gene, for example a
suicide gene able to cause cellular death. This gene would be expressed
when a heat-responsive promoter is activated (Fig. 2). Promoters are
carefully chosen to initiate the transcription of the gene only when the
increase in temperature occurs resulting in the expression of the thera-
peutic genes in a controllable way. This elegant approach allows the in
situ production of the gene with both spatial and temporal control.
In this manuscript we will review the scientific literature regarding
theuse ofmagnetic hyperthermia to trigger the release of drugs or to ac-
tivate therapeuticmolecules for cancer treatment. The presented results
are focused only on the use of iron oxide nanoparticles asmagnetic me-
diators for the heat production due to their low toxicity. The results will
be classified in two groups: a first group gathering representative exam-
ples of release of therapeutic drugs from a thermo-responsive matrix
and a second one focused on the activation of gene expression through
the increase in temperature. In both approaches, once themost relevant
properties of each nanostructure and the key factors involved in
the heat-triggered drug release using magnetic hyperthermia areFig. 2. Schematic representation for the in situ generation of therapeutic genes. A heat-
responsive promoter activates the expression of a therapeutic gene.
Please cite this article as: M. Moros, et al., Triggering antitumoural drug rel
Rev. (2018), https://doi.org/10.1016/j.addr.2018.10.004addressed, in vitro and in vivo reports will be discussed, highlighting rel-
evant aspects to consider for future developments.
2. Drug release using thermo-responsive matrices
2.1. Caused by bond break
During the last years, different types of covalent and non-covalent
bonds have been used to precisely release on demanddiversemolecules
uponAMF exposure (Fig. 3). In this sense, instead of usingmaterials that
are sensitive to heat, the molecules to be released are bound to the
MNPs via bonds that can be broken or destabilized when the tempera-
ture is increased.
The advantage of using non-covalent bonds (π-π interactions, and
hydrogen bonds not based on nucleic acids…) [27–31] is that the drug
does not have to be modified, resulting in overall simpler procedures
[32]. On the other hand, it is more challenging in terms of preventing
a premature release of the drug. Among non-covalent interactions, hy-
drogen bonds are the most popular (Fig. 3).
Hydrogen bonds can be used to directly bind the drug to theMNP, as
reported by Griffete et al. [31]. In this case, 11-nm MNPs containing
acrylic acid monomer were coated with molecularly imprinted poly-
mers (MIP) directly grown on their surface, using doxorubicin (DOX)
as a template. When applying an AMF (335 kHz, 7.17 kA/m at 37 °C),
the DOX was released in the absence of a global temperature elevation,
due to the destabilization of the hydrogen bonds between the drug and
the MIP. The cumulative release of the DOX under the AMF (60%) was
significantly higher than the one obtained by incubating the MNPs in
an external bath at the same temperature. Further, the importance of in-
troducing theDOX in the imprintingprocesswasdemonstrated by com-
paring the releasewith the one obtained by physically adsorbingDOX in
unprinted polymer MNPs. In this case, in the external bath 95% of theease and gene expression bymagnetic hyperthermia, Adv. Drug Deliv.
Fig. 3. Schematic representation of drug release strategies based on the break of non-covalent and covalent bonds.
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vantages. Lastly, the MNPs-MIP caused a 60% cell viability reduction in
PC-3 cells (human prostate cancer cell line) without temperature in-
crease after AMF application (700 kHz, 19.95 kA/m); the same viability
reduction was shown when using free DOX, without MNPs.
The extremely high specificity of nucleic acids base pairing allows
designing complementary DNA (deoxyribonucleic acid) strands that
will interact via non-covalent hydrogen-bonding. DNA molecules
show high physico-chemical stability, and high rigidity when they
stand as a double-strand [33]. Complementary strands can be modified
with a drug, which can be released upon local heating caused by AMF
application. Depending on the length of the strand and the composition,
it is possible tofine-tune themelting temperature (Tm), that is, the tem-
peraturewhere 50% of the strandswill dehybridize. For instance, Derfus
et al. demonstrated the possibility tomodulate theDNA release depend-
ing of the Tm, by designingMNPs functionalized with a DNA strand; af-
terwards it was hybridized with complementary DNA strands of
different lengths (and consequently diverse Tm) bearing fluorophores.
Low power electromagnetic field pulses (400 kHz-0.55 kW) could trig-
ger the release of the shortest complementary strand, while stronger
pulses (3 kW) were needed to release the longer strand [30]. A similar
strategy was used to assess the temperature gradient on the MNP sur-
face upon AMF excitation, by associating it with the DNA denaturation
profile [29]. By using three strands of different lengths, each one modi-
fied with a diverse fluorophore, it was also possible to correlate these
local temperatures with the distance of the DNA from theMNP surface,
and consequently to create an accurate spatial mapping of the temper-
ature. Despite the high potential of this triggering strategy, not many
examples of it can be found in the literature. Further, many of them
are proof of concept reports, where the experiments have been per-
formed in a test tube, but not in vitro or in vivo. [34].
Temperature responsive covalent bonds can be successfully used to
release drugs under an AMF in a highly controlled fashion (Fig. 3).
To this end, thermo-reversible Diels−Alder (DA) reactions and
thermo-labile azo-linkers have been described [13,35–38]. Among thePlease cite this article as: M. Moros, et al., Triggering antitumoural drug rel
Rev. (2018), https://doi.org/10.1016/j.addr.2018.10.004drawbacks associated to this strategy, the possible decrease of the bio-
logical activity of the drug when covalently attached to the MNP, and
the relatively high local temperatures (80–90 °C) that must be reached
in order to effectively break the bonds, must be taken into account. The
DA reaction is a thermo-reversible cycloaddition between a diene and a
dienophile to form a six-membered carbocycle, using furan and
maleimide moieties for instance [38]. The retro DA reaction (rDA) is a
suitable release method, although a high local temperature is needed
to achieve it. The possibility to use this kind of reactions to liberatemol-
ecules was first proposed by N'Guyen et al. [40].
A versatile ligand comprising different moieties was synthesized: it
contained a phosphonic acid group that could be bound to the iron
oxide surface ofMNP; further it carried two orthogonal clickable groups,
namely an alkynemoiety and a furan ring. The alkyne groupwas further
reacted with azide end-functionalized poly(ethylene glycol) (PEG)
through 1,3 dipolar cycloaddition in order to transfer the MNPs into
water and confer biocompatibility. On the other hand, the furan ring
was used to link a maleimide-functionalized cargo through reversible
DA chemistry. In this case tetramethylrhodamine-5-C2– maleimide
was conjugated as a model drug. Upon AMF exposure (332.5 kHz, 11.3
kA/m), the rhodamine (Rho) was released from the MNPs through a
rDA process, without any significant heating of the medium. More re-
cently, the possibility to release DOX fromMNPs based on the rDA reac-
tion has been also reported [39]. To this end, Zn0.4Co0.6Fe2O4@
Zn0.4Mn0.6Fe2O4 core-shell MNPs were modified with a furan moiety,
mixed with a maleimide-containing molecule through DA reaction,
and the DOX was attached via amide linkage. It was demonstrated
that under an AMF the DOX could be released, however, the experi-
ments should be performed at 50 °C to obtain an abundant release
(90%). When incubated with HepG2 cells (human hepatocellular carci-
noma), under an AMF (6200W, 1950 kHz) for 15min, 20% cell viability
was observed. Nevertheless, the sameMNPs without DOX also caused a
significant cell death under the same AMF conditions (45% cell viabil-
ity), demonstrating that the effect predominantly came from the gener-
ated heat and not from the DOX released by rDA.ease and gene expression bymagnetic hyperthermia, Adv. Drug Deliv.
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ported using these thermo-sensitive covalent bonds [41]. MNPs coated
with maleimide-modified silica were conjugated with ansamitocin de-
rivatives bearing a furan group. The liberation of the ansamitocin deriv-
ative via rDA reactionwas probed in a test tube by submitting theMNPs
to an AMF, reaching a temperature of 44.1 °C in 15 min. After 2 h of ap-
plying the AMF (2 kW, 780 kHz), the supernatant was collected and
used to treat Huh-7 cells (human liver carcinoma), finding that cell pro-
liferation decreased over time when compared to non-treated groups.
In vivo studies were conducted by intratumourally injecting the MNPs
into tumours generated in immunodeficient mice using Huh-7 cells. In-
termittent cycles of AMF were applied, so that the temperature of the
tumour (measured from outside) could only rise to approximately 42
°C. A decrease in the tumour size was observed during the first week
due to increased apoptosis and reduced proliferation, although after-
wards an increase in tumour volume was found. As a control, a mouse
injected with the same MNPs but not subjected to the AMF was used,
therefore, the solely effect of the heat generated by the AMF and the
MNPs cannot be distinguished from the effect of the drug release.
Another type of thermo-responsive covalent bonds that have been
used to release drugs upon AMF application are azo bonds. In a
pioneering report, a PEGylated (poly(ethylene glycol)) azo-linker was
used as a thermo-labile bond to functionalizeMNPs,whereDOXwas co-
valently attached to the azo linker [37]. PEG molecules of different
lengths were used as spacers. The MNPs were subjected to an AMF for
1 h (334.5 kHz, 13.5 kA/m) finding that for the shorter PEG (500 Da
molecular weight) about 36% of the drug was released, while for the
longer PEG (6000 Da molecular weight) only 15% was liberated. Yoo
et al. went a step further by engineering MNPs that could promote
thermoresistance-free apoptosis, what they coined as resistance-free
apoptosis-inducing magnetic nanoparticle (RAIN) [36]. It is widely
known that Heat Shock Proteins (HSPs) can shield cells from apoptosis,
and therefore are involved in the acquisition of tumoural
thermoresistance [42]. The RAIN consisted of an inhibitor of HSPs
(geldanamycin, GM) linked via an azo linker to zinc-doped iron oxide
MNPs (Zn0.4Fe2.6O4). After 1 h under AMF application (500 kHz, 37.4
kA/m) at 43 °C, a complete release of GM was found, whereas only 7%
was released when using a water bath at the same temperature.
When RAIN were incubated with MDA-MB-231 breast cancer cells,
100% of death could be found due to apoptosis after 60 min upon AMF
treatment, while only 25% of cells died when using MNPs not bearing
GM. Interestingly, HSP90 expression levels were lower in RAIN-
treated cells, demonstrating that the use of a HSP inhibitor makes cells
more sensitive to apoptosis. Furthermore, RAIN were intratumourally
injected in mice bearing MDA-MB-231 xenograft tumours and exposed
to the AMF for 30min. Tumour volume changes weremonitored during
14 days, finding that RAIN-treated tumours were completely sup-
pressed at day 8.Fig. 4. Schematic representation of the two different approaches generally used for the
development or combined polymer and MNPs systems for drug release using magnetic
hyperthermia. (left) Coated MNPs and (right) MNPs embedded in the thermo-
responsive material.2.2. Caused by the matrix transformation
2.2.1. Polymers
The combination of MNPs and polymers is not a recent issue. These
macromolecules have been commonly used for the stabilization of
MNPs in aqueous media, especially for biological applications [43]. For
magnetic hyperthermia-based drug delivery, the use of thermo-
responsive polymers is frequent. These polymers change their structure
or miscibility when certain temperature is reached. The temperature at
which a polymer undergoes a reversible change of phase is called
“lower critical solution temperature” (LCST). A biocompatible polymer
with a LCST slightly above the body temperature is quite interesting,
as it can be exploited to load and release a drug at convenience. Differ-
ent polymers with these characteristics can be found in the literature,
including poly-lactic acid (PLA), poly(ethylene glycol) ethyl ether
methacrylate-copoly(ethylene glycol) methyl ether methacrylate,Please cite this article as: M. Moros, et al., Triggering antitumoural drug rel
Rev. (2018), https://doi.org/10.1016/j.addr.2018.10.004Pluronic® F-127 (F127), poly(methylmethacrylate) (PMMA) or poly-
n-isopropylacrylamide (PNIPAM) among others [44].
As we will present along this section, MNPs have been widely used
as heat source for the polymer change of phase. Different approaches
have been explored for the development of a polymer-MNPs system.
The MNPs can be found coated with or embedded in the thermo-
responsive material (Fig. 4).
First, a widely utilized arrangement is represented by polymer-
coated MNPs. In this strategy, the MNPs are covered with a thermo-
responsive and biocompatible polymer, which can simultaneously be
loaded with a therapeutic molecule [45–48].
Ding and co-workers functionalized magnetic nanocubes with a
thermo-sensitive sol-gel block copolymer [45]. Folic acid-decorated
F127 gels were used as the coating agent. F127 is an amphiphilic block
copolymer with an excellent biocompatibility. It interacts with the
nanocubes and allows the loading of paclitaxel (PTX), the anticancer
drug used in this work. The heating efficiency of the nanosystem was
measured at different conditions of frequency and current strength, as
well as at different concentrations of the sample. An increase of up to
22 °C in 10minwas achieved at 2.0mg/mL (200 kHz, 300A)with anop-
timized drug loading - 53% drug loading efficiency and 9.58% drug load-
ing content using a ratio PTX: MNPs = 2:10 (w/w). The optimized
system was further used to monitor the release of the drug in time,
with and without the application of an AMF (Fig. 5). A negligible drug
release was observed when the AMF was off (b10% in 24 h, at 37 °C);
conversely, a rapid release occurred when the field was turned on
(40.3% in 10 min, 93.4% after 2 h of AMF application). These results
also showed that the system could be precisely controlled. When a re-
peated AMF on-off sequence was applied, the release of the loaded
drug stopped when the AMF was off, due to the return of F127 to solid
phase. The cytotoxicity of the nanoconstructs – both drug-free and
loaded –was evaluated in vitro in HeLa cells, with and without AMF ap-
plication. Under no magnetic stimulus, both nanosystems had good
cytocompatibility, with low percentages of cell death. When the AMF
was applied, they showed a time-dependent death. Free nanocubes in-
duced 70% cell death in 50min of hyperthermia time,while cells treated
with PTX-loaded nanocubes showed almost 90% reduction of their via-
bility with the same hyperthermia time.
MNPs-embedding polymers are different from the previous exam-
ples because here the system consists of a polymeric nanoparticle in
which both MNPs and the drug are inserted. Whereas in the previous
approaches each nanoparticle was covered by the polymer, in here the
polymer is the main entity, and it contains several MNPs as well as the
drugs [49–53]. Hydrogels can be included into this category. They con-
sist of a three-dimensional polymeric structure mainly composed by
water, but insoluble due to the cross-linking [54].ease and gene expression bymagnetic hyperthermia, Adv. Drug Deliv.
Fig. 5. Release profiles of PTX frommagnetic nanocubes functionalized with a thermo-sensitive sol-gel block copolymer under exposure to an AMF. (right) Delayed release profiles under
exposure to an AMF. (left) Release profiles under pulsatile AMF. Reprinted from Publication Materials Letters 2016, 175, 236–240. Copyright (2016), with permission from Elsevier [45].
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Cazares-Cortes and co-workers. They developed a pH-responsive and
thermo-responsive polymer-based nanogel loaded both with MNPs
and an anticancer drug, DOX (Fig. 6) [50]. The gel was comprised by
oligo(ethylene glycol) methyl ether methacrylate and was prepared
by radical copolymerization. To obtain magnetic nanogels, 11.5 nm
iron oxide MNPs were further encapsulated in the gel at different
MNP:nanogel ratios (between 9 and 66.7 wt%), showing optimal stabil-
ity and homogenous distribution of theMNPs in the polymeric structure
at MNP mass ratios lower than 50 wt% (as revealed by dynamic light
scattering, DLS, and transmission electron microscopy, TEM). After-
wards, DOX was encapsulated in the magnetic nanogels. The tempera-
ture and pH dependence of the system was firstly studied by DLS.
Changes in the hydrodynamic diameter were observed when tempera-
ture or pH varied, reversibly changing from a swollen to a collapsed
state. Both low pH and high temperature induced a collapsed state. At
the same temperature, nanogels had a 300 nm difference in hydrody-
namic diameter at different pH values (650 nm at pH 7.5 and 350 nm
at pH 5.5). Besides, pH influenced the collapse temperature (54 °C atFig. 6. TEM images of nanogels loaded with different amounts of MNPs and an anticancer drug,
Copyright (2017) American Chemical Society [50].
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the 37.5wt%magnetic nanogels, as this value represented the best com-
promise betweenMNP content and stability. The DOX releasewasmea-
sured with and without the application of an AMF (335 kHz, 12.0 kA/m,
30min pulses) at pH 5.0 and 7.5. After 4 h, the release was 96% and 24%
respectivelywithout the application of the AMF.When theAMFwas ap-
plied, the releasewas considerably accelerated, achieving 100% and 47%,
respectively. At pH 7.5, the release doubled its value thanks to the AMF.
The authors performed cytotoxicity studies of the nanogels using PC-3
cell lines, derived from human prostate. The cell viability was not af-
fected by themagnetic nanogels without DOX, neitherwith norwithout
AMF (471 kHz, 14.4 kA/m, 2 h), indicating that hyperthermia itself does
not produce a direct negative effect on cells. The half-maximal inhibi-
tory concentrations IC50were 26, 19 and 8 μM for the free drug, nanogel
alone and nanogel + AMF (same conditions as before), respectively,
proving the enhancement of anticancer effect of DOX with this system.
The authors further assessed the intracellular localization of the DOX by
confocal microscopy, showing that nanogels increased the amount of
DOX present in the nuclei for the same drug concentration as DOXDOX. Adapted with permission from (ACS Appl Mater Interfaces 2017, 9, 25,775–25,788).
ease and gene expression bymagnetic hyperthermia, Adv. Drug Deliv.
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higher DOX fluorescence signal intensity in the nuclei than those
treated without the AMF, which, in turn, showed higher DOX nuclear
fluorescence than cells treated with the free drug.
As shown above, test tube and in vitro trials reflect the potential of
the thermo-sensitive polymers-MNPs combination as drug delivery
and cancer therapy agents. Different configurations show highly con-
trollable systems with variable efficiencies and release kinetics (from
minutes to days). This last facet can become a great advantage, as it al-
lows the release time to be extremely tunable, using the system that
best adapts to the treatment needs.
After the promising results in vitro, the therapeutic systemsmust be
assessed in vivo before entering clinical trials. Several studies reporting
in vivo experiments confirm the ability of thesemagnetopolymeric enti-
ties to eradicate a tumour completely (Fig. 7). In most cases, they also
prevent the tumour to appear again weeks later. It is the case of mag-
netic nanoclusters coated with carboxylic polypyrrole loaded with
DOX and further functionalized with folic acid [46]. This polymer had
a LCST of around 44 °C. At that temperature, it could release N60% of
DOX in 20 min, a value that reached 90% at 46 °C. The polymer coated
MNPs were tested in immunodeficient female CB17 mice inoculated
with human multiple myeloma cells. The animals were divided in six
groups to compare the different treatment modalities: no treatment,
nanoparticles without AMF, AMF (in all cases 230 kHz, 8 kA/m,
20 min) without nanoparticles, chemotherapy alone, magnetic hyper-
thermia alone, and the combination. Mice treated with the whole sys-
tem (loaded polymeric MNPs under AMF) showed a survival rate of
100% 200 days after treatment. Meanwhile, all the other groups had a
0% survival rate after 120 days. Besides, the complete treatment
succeeded in the complete removal of the tumour only 8 days after
AMF exposurewith no regression,while the other systems could reduce
its volume, but not cure it. Of note, no toxicity of the nanoparticles was
detected.
The following examples are remarkable as they prove the efficacy of
nanotechnologically driven drug release with thermo-sensitive poly-
mers against resistant tumours. Many cancer types, although they ini-
tially respond to treatment, end up by developing resistance to the
drug. In such cases, elevating the dose might result in both increased
toxicity and low effectiveness [55]. Magnetic nanoformulations allow
the specific delivery and controlled release of the drugs. Furthermore,
the heat produced by the MNPs enhances the effect of the chemother-
apy, sensitizing resistant cells, as shown in many other studies [56–58].
Tumour necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) is a cytokine that selectively induces apoptosis when it binds
to DR4 and DR5 receptors, over-expressed in many cancer cells. Thus,Fig. 7. Synergistic effect between chemotherapy and MHT. Photographs of non-treated
mice, mice treated with chemotherapy, mice treated with MHT, and mice treated with
the combination of MHT and chemotherapy 45 days after treatment. Adapted from
Theranostics 2014, 4, 834–844. [46].
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treat certain cancers [59]. However, some common malignant tumours
are TRAIL-resistant, namely melanoma, glioblastoma or pancreatic can-
cer. In this context, Zhang and Song synthesized a negatively charged
poly(organophosphazene) (PPZ) that allows the electrostatic attach-
ment of the positively charged TRAIL. This work is as well a representa-
tive exhibition of the use of doped iron oxide nanoparticles, as they used
Zn0.47Mn0.53Fe2O4 nanoparticles embedded in the polymer to obtain a
magnetic nanohydrogel [53]. The effect of the treatment was assessed
in vivo using BALB/c nude mouse bearing U-87 MG tumours (TRAIL-re-
sistant human glioblastoma cells). The authors followed the tumour
volume evolution after 1 or 2 cycles of hyperthermia, maintained
around 43 °C for 1 h by applying an AMF of 13.3 kA/m and 366 kHz.
AMF applications were carried out at day 1 and 3 post-injection. A
small tumour reduction was observed in nanohydrogels alone-treated
mice compared to control (V/Vinitial = 13.6 and 15.3 respectively at
day 25 post-injection), probably due to a slow but sustained TRAIL re-
lease. When a single hyperthermia cycle was applied the V/Vinitial ratio
reduced to 6.9, and to 1.3with the 2 cycles treatment. The last reduction
was attributed by the authors to an additional release of TRAIL from the
nanosystem. Although no complete tumour regression was obtained, a
clear effect of resistance reductionwas achieved thanks to the combina-
tional treatment and drug delivery system.
The last example illustrates a more complex formulation able to
transport two different drugs simultaneously and release them at dis-
tinct times. It is a representative case of multidrug delivery, which can
be very promising, as the combination of two different anticancer
agents can avoid the development of multidrug resistance (MDR) can-
cers [60]. In this very complete work, Xie et al. presented a self-
healing thermo-sensitive magnetic hydrogel that allows the asynchro-
nous release of DOX and docetaxel (DTX) [61]. The asynchronous
release of both therapeutic molecules might be a potential way to over-
come theMDR issue. The whole construct consist of three components:
(1) DOX, (2) DTX-loaded poly(lactic-co-glycolic acid) nanoparticles
(DTX/PLGA NPs) and (3) DF-PEG-DF modified iron oxide nanoparticles
(PEG-MNPs, DF=4-Formyl-benzamide). Those three elements are em-
bedded in a chitosan/DF-PEG-DF matrix. DF groups interact with the
amine of the chitosan, giving place to the cross-linking. The system is
denoted as DDMH (dual-drug-loadedmagnetic hydrogel). The interest-
ing point of this approach is that, after 24 h of incubation at 37 °C, no
DTX was released whereas N10% of DOX did. It has to be noted that
the release assays lasted up to one month (when ~ 80% of release of
both drugs is achieved). The low rate of release can be advantageous
for treatments that require longer periods of drug administration.More-
over, the response to the application of an AMF (282 kHz, 19.99 kA/m)
was also different for each drug. While DOX release was barely in-
creased, DTX release became significantly faster using magnetic hyper-
thermia. This difference provides the possibility to regulate and control
the co-delivery process of both drugs. In cytotoxicity assays with triple
negative breast cancer cells (MDA-MB-231), the system showed a
time-dependent response, and a clear synergistic effect of both drugs
comparedwith their administration alone. After 48 h incubation, the vi-
abilitywas 19.6% if noAMFwas applied, and5.6%with the application of
AMF. The system was also tested in vivo, with MDA-MB-231 tumour-
bearing nude mice. An intratumoural injection of saline and DDMH
was performed, and after 24 h, mice were exposed to an AMF
(282 kHz, 19.99 kA/m, 10min). In DDMH injected tumours, the temper-
ature reached 48 °C, whereas in saline injected tumours only a 1.3 °C in-
crease was reached compared to body temperature. With a single
injection, DOX hydrogel and DTX/PLGA NPs separately inhibited only
partially the tumour growth compared with saline. The combined
DOX and DTX/PLGA NPs hydrogel achieved much better results. How-
ever, the best outcome came from the DDMH when exposed to AMF.
That was probably due to the enhanced drug delivery aswell as a possi-
ble synergy of chemo- and hyperthermia therapy. Finally, toxicology of
DDMH was assessed (biochemistry, hematology and histologicalease and gene expression bymagnetic hyperthermia, Adv. Drug Deliv.
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nanosystem presents no obvious toxicity.
2.2.2. Liposomes
Since their discovery in the 1960s by A.D. Bangham, liposomes have
brought about a major revolution in the field of drug delivery. Lipo-
somes are very simple structures based on natural or synthetic phos-
pholipids, amphiphilic molecules that in the presence of an aqueous
medium orient in a spontaneous manner to avoid the interaction of
their apolar regions with water. Subsequently, a double-walled hollow
sphere with an aqueous core is formed. These particular conformations
exhibit unique properties that can be very useful for drug delivery
applications. First of all, they present high biocompatibility due to the
low reactivity of lipids. Secondly, their particular compartmentalisation
allows the encapsulation of both hydrophobic and hydrophilic
chemotherapeutical agents. Thirdly, liposomes can be synthetized
with range of sizes between 50 and 450 nm for promoting the passive
targeting trough enhanced permeability and retention (EPR) effect in
tumours [62]. Due to all of these advantages, liposomes have been the
first nanostructured device to be approved for the delivery of drugs
for human use by the FDA.
In this regard, in 1988 Cuyper et al. described for the first time the
encapsulation of MNPs of 14 nm inside of a lipid bilayer, coining the
term “magnetoliposomes” [63]. Since then, the combination of MNPs
with liposomes in single nanoplatforms has acquired great relevance
for the development of multifunctional therapeutic devices. Due to the
singular properties of MNPs, magnetoliposomes could overcome the
limitations of traditional liposomes in drug delivery applications. First,
in terms of selectivity, MNPs provide magnetic guidance for in vivo tu-
mour targeting. García-Jimeno et al. demonstrated the preferential ac-
cumulation in the target tissue of magnetoliposomes intravenously
administered inmice after the application of an externalmagnet, reduc-
ing at the same time the biodistribution in other organs relatedwith the
clearance from the blood by the immunological system as the liver or
spleen [64]. Furthermore, the functionalization of liposomes with
MNPs increased their colloidal stability, while also limiting the passive
release of the drugs loaded [65,66]. Finally, the release of the drug at
the target site can be triggered by the heating properties of MNPs in
the presence of an electromagnetic field and therefore, improve the
therapeutic efficiency [67]. Magnetoliposomes can suffer changes in
their structure and permeability and release their payload in a control-
lable way. This change of permeability is linked to the melting temper-
ature (Tm) of the lipid bilayer, atwhich there is a transition from the gel
to the fluid phase of the bilayer, resulting in the subsequent diffusion of
the drug. At this point it is important to remark that the composition of
the lipid bilayer plays a key role and lipidswith Tmabove the physiolog-
ical temperature (37 °C) are needed to avoid passive release [68].
Magnetoliposomes with higher Tm will present slower and inefficient
release but this can be compensated by a goodMNP loading and heating
efficiency. For instance, dipalmitoyl-sn-glycerophosphocholine (DPPC,
Tm of 41.5 °C), is one of the most reported lipids used on
thermoresponsive liposomes because it presents amelting temperature
close to the clinically relevant hyperthermia values. In addition, surface
grafting of magnetoliposomes with polymers, for example PEG, allows
to change the gel-fluid phase transition and opens the possibility to de-
velop new more versatile formulations [69].
Magnetoliposomes can acquire three different structures depending
on the localization of theMNPs: inside the core, embedded in thebilayer
or attached to the surface (Fig. 8).
The difference in the formation of each of these structures lies in the
size and coating of the MNPs. In the case of the core type
magnetoliposomes the limiting factors are the size of the MNPs – their
diameter has to be lower than the one of the liposome core - and their
coating, which must be hydrophilic, while in the case of the liposomes
with the MNPs embedded in the bilayer, the MNPs have to be hydro-
phobic and smaller than the thickness of the lipid bilayer (b 6.5 nm)Please cite this article as: M. Moros, et al., Triggering antitumoural drug rel
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mainly through electrostatic interactions and their maximum size is
limited to 20 nm in diameter, as otherwise the liposome can be
disrupted and form a bilayer around the MNP [71,72].
We should also mention that the type of structure influences the
magnetoliposome functionality with respect to drug delivery. In this re-
gard, the localization ofMNPs embedded on the lipid bilayer or attached
to the surfacehave the advantage of a direct transfer of the heat released
by theMNPs to the lipid bilayer,with amore efficient controlled release.
This effect was described by Amstad et al. who observed that iron oxide
nanoparticles embedded in the lipid bilayer induced an increase of the
permeability without disruption of the liposome after the application
of a high frequency magnetic field [73]. Nevertheless, in the case of
core-loaded magnetoliposomes the increase of temperature at the
core has to reach the lipid bilayer and this process can be hampered
by fast heat dissipation in the aqueous liposome core [74]. However, it
has been demonstrated that the thermally stimulated lipid phase tran-
sition is not the only mechanism that can induce the drug release. For
example, Nappini et al. suggested for the first time that nanoparticle
motions in the liposome core were themainmechanism of drug release
in the presence of low frequency AMF as a consequence of the alteration
of the bilayer permeability. The higher release was described at a field
frequency of 5.82 kHz, 79.77 kA/m and at an exposure time of 50 min,
enhancing the hypothesis of the shaking effect of the nanoparticles
[75]. Later on, Chen et al. described for the first time the synthesis of
bilayer-decorated magnetoliposomes and their stimuli responsive re-
lease properties [76]. They observed that after radio frequency heating
at 2.1 kA/m and 281 kHz, some structural changes in the
magnetoliposomes appeared because of the fusion of neighbour lipid bi-
layers. They could demonstrate that radio frequency heating induced
both permeabilization and partial disruption of the bilayer. Even more,
Podaru et al. reported the release of drug from core-loaded
magnetoliposomes based on short magnetic pulses (214.8 Hz, 2393
kA/m) that induced a mechanical motion of the MNPs without a signif-
icant increase in local temperature. This motion generates ultrasounds
that have an effect on the stability of the bilayer and promote the release
of the liposomes' cargo [77].
Finally, well-defined drug released kinetics are mandatory for a fu-
ture clinical application. In this sense, the encapsulation efficiency of
MNPs in themagnetoliposomes, which is dependent on their size, coat-
ing and stability, plays a key role. Shaghasemi et al. reported an exhaus-
tive study of the parameters that can influence the heat-induced
controlled release of drugs [68]. Different PEGylated magnetoliposomes
of around 50 nm in diameter composed of four different
phosphocholine lipidswith different Tm andwith iron oxide nanoparti-
cles of 3.9 nm in diameter incorporated in the membrane were
analysed. It was demonstrated that the concentration of MNPs in the
membrane had an effect on the load release by exposure to an AMF.
The higher the weight fraction of nanoparticles, the higher were the
rate of release and the total amount released. However, weight fractions
above 4% showed a lower stability and higher passive release (in the ab-
sence of an AMF) due to the formation of MNP aggregates in the mem-
brane. In addition, it was demonstrated that the release kinetics was
linked with the Tm of the lipid composition. In the case of the
magnetoliposomes with the lower lipidic Tm only one pulse of
228 kHz and75.5 kA/m for 4minwas enough to reach themaximum re-
lease, while for the ones with higher Tm an increase in time exposure to
the AMF until 8 min was necessary to observe the same release using
the same AMF conditions.
Many in vitro studies have been published up-to-date and all of them
follow the same formulation analysis [66,78–82]. First of all the thermal
sensitivity of the magnetoliposomes is analysed. Depending of the lipid
composition and the incorporation or not of polymers, the Tm can
change and the stability of the formulation can be also affected. An
ideal magnetoliposome should have a very low permeability at physio-
logical temperature, while promoting drug delivery at the designed Tm.ease and gene expression bymagnetic hyperthermia, Adv. Drug Deliv.
Fig. 8. Schematic representation of the three different magnetoliposome structures typically used: (left) core loaded magnetoliposomes, (centre) bilayer-embedded magnetoliposomes
and (right) surface decorated magnetoliposomes.
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ciency to ensure that the heating produced will be enough to promote
the drug release and that there is a sufficient amount of drug for a che-
motherapy application. The active targeting of tumoural cells is also ex-
amined for some formulations that include targeting agents as for
example folate. Finally, in vitro cytotoxicity is tested with or without
AMF to check the heat-triggered chemotherapy application of the
formulation.
For instance, with the objective to develop a combined thermo-
sensitive and targeting formulation, Pradhan et al. prepared a
magnetoliposome formulation with a well optimized lipidic composi-
tion of [1,2-dipalmitoyl-sn-glycero- 3-phosphocholine, cholesterol,
1, 2-distearoyl-sn-glycero-3- phosphoethanolamine-N-[methoxy(poly-
ethylene glycol)-2000] and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[folate(polyethylene glycol)-2000] (DPPC:
cholesterol:DSPE-PEG2000:DSPE-PEG2000-Folate) at 80:20:4.5:0.5 M
ratio to reach a significant release of DOX at 43 °C (clinical relevant hy-
perthermia temperature) [78]. An encapsulation efficiency of about 85%
for DOX and a temperature sensitive release of approximately 52% in
50% foetal bovine serum (FBS) at 43 °C were obtained. Worth noting,
a relatively high passive release of about 17% after 1 h incubation in
50% FBS at 37 °C was observed. The dual active targeting induced by
the folate and the MNPs in the presence of an external magnetic field
was demonstrated in HeLa (human cervical carcinoma) and KB
(human epidermoid carcinoma) cells (which overexpress folate recep-
tors). A comparison of the system under study (MagFolDOX) with aFig. 9. Cytotoxic effect of the different liposome formulations and free DOX in KB (a) and He
Reprinted from Publication Targeted temperature sensitive magnetic liposomes for thermo-ch
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Rev. (2018), https://doi.org/10.1016/j.addr.2018.10.004non-targeted version without folate (MagPEGDOX), non-magnetic
folate-targeted liposomes (FolDOX), non-magnetic stealth liposomes
(PEGDOX) and the commercial formulation Caelyx® (DOX-loaded lipo-
some) confirmed its higher cytotoxic effect under permanent magnetic
field (Fig. 9). In addition, the combined treatment (magnetic targeting
+ AMF-induced hyperthermia) with MagFolDOX (30 μM DOX) im-
proved tumour cell killing effect. KB cell viability lower than 7% after
the exposure to an AMF of 12 kA/m and 290 kHz for 1 h at 43.5 °C
was reached.
Despite the positive results in tumour cell death presented by
Pradhan and co-workers, the high passive release observed at 37 °C rep-
resents an important limitation for future in vivo applications. In view of
this situation, two years later Kulshrestha et al., described a much sim-
pler magnetoliposome formulation based on only two lipids: 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1-palmitoyl-2-
oleoyl-sn-glycero-3-phospho-rac-glycerol (PG) [80]. These
magnetoliposomes displayed a much lower passive release at 37 °C,
with a PTX release of only 1.2%; at 43 °C and under AMF application
(10 kA/m and 423 kHz), the release reached 55.58%. In addition, very
promising results for combined hyperthermia with drug delivery were
reported, with an 89% of cell death using HeLa cells.
Bilayer-embedded magnetoliposomes have also undergone in vitro
studies to evaluate their potential use for in vivo experiments. Chen
et al. developed a mixed formulation of magnetoliposomes containing
5 nm oleic acid maghemite nanoparticles but also with bare liposomes
(without MNPs), both loaded with DOX (2 μM) [66]. After theLa cells (b). Permanent magnetic field (MF) and free folic acid (FA) effects were tested.
emotherapy. Copyright (2010), with permission from Elsevier. [78].
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carcinoma cell line, cell viability studies confirmed the stability of the
magnetoliposomes in terms of passive release. The DOX release was
triggered with a radiofrequency electromagnetic field (field strength
7.1 × 104 kA/ms for 30min) and revealed a decrease of 40% in the cellu-
lar viability after 8 h and 100% after 24 h.
Regarding the in vivo performance of these systems for cancer treat-
ment, the first positive results based on thermo-chemotherapy were
published in 2009. Yoshida et al., described for the first time the
in vivo tumour regression in mouse models with human gastric MKN-
45 cancer cells after the intratumoural injection of docetaxel
magnetoliposomes in combination with magnetic hyperthermia [83].
Tumour volume was reduced for magnetoliposomes with a DTX con-
centration of 56.8 μg/mL after the application of an AMF (6.36 kA/m at
478 kHz) for 30 min with a power of 0.5 to 1.5 kW to reach a controlled
tumour temperature about 42 °C for 30 min. On the contrary, mice
treated with same concentration of DTX-loaded magnetoliposomes
but without AMF application, mice treated with DTX with and without
AMF andmice treated withmagnetoliposomes without the chemother-
apeutic drug and with AMF sustained a gradual tumour growth. Fur-
thermore, two mice (from a group of six) survived N24 weeks after
the combined treatment of DTX-loaded magnetoliposomes and AMF
but all mice died by 15 weeks after the same treatment without AMF.
Since then, a few similar reports have been published, including also
the combination of magnetoliposomes with photosensitizer drugs for
combined MHT and photodynamic therapy [84–86]. Over the past two
years the attention has been focused on the development of multifunc-
tional magnetoliposomes with active targeting, thermo-sensitivity and
imaging properties for cancer theranostics [87,88]. For instance, Guo
et al. have recently described a multifunctional thermo-sensitive
bilayer-embedded magnetoliposome that combines an active targeting
(methotrexate as a surface ligand for folate receptor-overexpressed
cancer cells) with DOX and a fluorescent dye (Cy5.5) for tumour imag-
ing [88]. The intravenous injection of the system in mice bearing HeLa
tumourmodels confirmed the tumour dual (magnetic and folate recep-
tor) targeting efficiency over 8 h after the application of amagnet on the
tumour region by fluorescence microscopy and MRI. Taken togetherFig. 10. (a) Schematic representation of the magnetoliposome formulation (MTX-MagTSLs) (b
rate (d) after the intravenous injection ofMagTSLs andMTX-MagTSLswith a constantmagnetic
Reprinted from Publication Light/magnetic hyperthermia triggered drug released from multi-f
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stimulation with an AMF (500 kHz, 20 kA/m, 5 min) and a NIR (near in-
frared irradiation) laser (808 nm; 0.8 W/cm2) and a 100% survival rate
of mice within 14 days, these results confirmed the potential of multi-
functional liposomes for cancer theranostics (Fig. 10).
2.3. Using switchable gates
As it has been explained in the previous sections, there aremany dif-
ferent stimuli-responsive nanomaterials that can be used to achieve a
controlled drug release for improved cancer treatment purposes. All
these approaches are on demand drug vehicles and can be remotely ac-
tivated to deliver their cargo in the desired environment, with spatio-
temporal control, only when the external stimulus is on. However, it is
desirable to achieve switchable systems that could be activated when
the stimulus source is on and come back to their original state when
the stimulus is removed. This would facilitate a repetitive activation of
the drug release once the nanomaterial has reached the tumour site.
This switchability is a very promising feature for a drug delivery system
as itmakes possible to better control the amount of drug that is released
in the tumour; furthermore, repetitive activations give the possibility to
perform several cycles of drug release and tumour treatment.
In addition to some approaches based on polymeric nanostructures
described in previous sections, an alternative design for switchable sys-
tems is based on a platform composed of two different materials: a core
composed of a porous material with large mesoporous volume, where
the therapeutic molecule is retained, and a coating that blocks the
pores, acts as gatekeeper preventing the drug release in physiological
conditions and is able to change its conformation in the presence of
the stimulus, allowing the tailored drug release (Fig. 11). The conforma-
tion alteration should be reversible, changing from the capping state to
the uncapping state when the stimulus is OFF and ON, respectively.
Among thematrix materials used for these delivery systems there is
one type that is by far the most used one, namely mesoporous silica
(Fig. 12) [15,16,89–95]. This material has unique characteristics that
make it a good candidate for drug delivery applications, such as its
high surface area, good biocompatibility, large pore volume and large) Dual (AMF + laser) triggered DOX release. Tumour growth curves (c) and mice survival
field (CMF), AMF or DUAL stimulimode at aDOX dose of 2mg/kg every treatment (2days).
unctional thermo-sensitive magnetoliposomes for precise cancer synergetic theranostics.
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Fig. 12. Schematic representation and selected transmission electron images from
Mesoporous structures used to carry therapeutic molecules in the frame of switchable
systems with two different compositions: Silica and Iron Oxides. Adapted with
permission from [97] Copyright (2012) American Chemical Society. Adapted from [98] Li-
censed Content Publisher JohnWiley and Sons.
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terms, the nanocarriers based on mesoporous silica nanoparticles
(MSN) can be of different shapes,with thedrugmolecules placedwithin
the pores. The pores are externally blocked by some cap ligands that
work as gatekeepers of the drug. There are several examples of different
thermo-responsive cap ligands, the most commonly used ones being
phase change materials as thermo-sensitive polymers [15,90,93,95], al-
though there are also few approaches that use small molecular
nanovalves for blocking individual pores [16,91,92].
In the first part of this section, we will review the use of thermo-
sensitive polymers as gatekeepers, awidely used strategy for drug deliv-
ery nanocarriers. Baeza et al. used the copolymer poly(ethylenimine)-b-
poly(N-isopropylacrylamide (PEI/NIPAM) with a double purpose [93].
On the one hand, the polymer is responsible of blocking the pores of
the mesoporous matrix avoiding/allowing the release of the model
cargo molecule (fluorescein) depending on the temperature. On the
other hand, the polymer is able to electrostatically retain a second
model molecule, in this case a protein (Soybean Trypsin inhibitor
typeII-S). Results showed that the nanocarrier was able to release the
two different molecules under the application of an AMF (24 kA/m,
100 kHz) for 6 h. The release of the surface-retained protein was similar
to the one observed when externally heating the nanocarrier at 45 °C,
but the release of the fluorescein, located inside the nanocarriers, was
much faster than the one observed under external heating. Other ap-
proaches are based on the use of polymers that respond to more than
one stimulus; typically one internal and one external stimulus are com-
bined in order to ensure a better drug release. The combination of heat
and pH stimuli is very appropriate and is being investigated for cancer
treatments. Guo et al. designed a nanocarrier based on a Fe3O4 core
and a mesoporous silica shell functionalized with the thermo-sensitive
polymer poly[(ethylene glycol)-co-(L-lactide)] (P(EO-co-LLA) that has
a sol-gel transition at 45 °C. The drugmolecule, DOX, was loadedwithin
the silica matrix and release experiments concluded that the best drug
release profiles were achieved when submitting the nanocarrier to an
AMF (250 kHz) at a pH of 5.8. In vitro experiments showed that the
drug loaded nanocarriers exhibited a quite important concentration-
dependent cytotoxicity effect (from 75% to about 30% of cell viabilityFig. 11. Schematic representation of the release of therapeutic molecules usingmesoporous stru
thermo-responsive materials. Irreversible approaches are based on the coating degradation to
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Rev. (2018), https://doi.org/10.1016/j.addr.2018.10.004with 3.125–50 μg/mL DOX, respectively) after 6 h of incubation. How-
ever, after the exposure to the AMF a reduction in the cell viability
was observed, proving the efficacy of the nanocarrier [15]. Other type
of thermo-sensitive polymers can be the temperature-degradable ones
(Fig. 11). The main inconvenience of this type of polymers is that they
do not fulfil the switchability requirement and although different stim-
uli conditions could trigger a different response in terms of amount of
released drug, the polymer would never recover its physiological statectures. Reversible approaches are based on the blocking and unblocking of the pores with
open the pores. Once the pores are unblocked, the therapeutic molecule can be released.
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of magnetic core-shell (Fe3O4-SiO2) particles functionalized with PEG
through a thermo-labile azo-bond (see section 2.1. about release caused
by bond break, Fig. 3) [90]. Themolecule used asmodelwas Rho6G. The
authors performed test tube release and in vitro cytotoxicity experi-
ments, the results indicated that the nanosystem was able to release
the contentwhen exposed to anAMF even though nomacroscopic tem-
perature increase was observed and that no cytotoxicity effect was
detected.
As previously mentioned, there are also a few examples in the liter-
ature that use other types of gatekeepers different from polymers. Some
small molecules can be used to block individual pores. So is the case of
the work of Rühle et al., who designed a nanocarrier made from MSNs
functionalized with maleimide. An adamantane group was attached to
the maleimide though a thermally reversible [2 + 4] DA cycloaddition
with a furan-modified linker (for more details on the DA cycloaddition,
see the section about release caused by bond break). This system can
undergo a cycloreversion when exposed to an external AMF (370 kHz,
5kw, 30 min), resulting in the release of its content [92]. Another ap-
proach in which nanovalves were used is the one reported by Thomas
et al., who synthesized a nanocarrier consisting of MSNs whose surface
was modified with pseudo-rotaxane as thermo-responsive gatekeeper
[91]. This nanovalve remained closed at physiological temperature
and openedwhen heated; release test tubes experiments demonstrated
that the nanovalve was opened when the nanocarrier was submitted to
1min of AMF evenwhen nomacroscopic temperature increase was ob-
served. In vitro experiments performedwithMDA-MB-231 cells showed
that although the nanocarrier without the drug produced about 15% of
cell after the exposition to the AMF (37.4 kA/m, 500 kHz), the cells incu-
bated with drug-loaded nanocarrier and submitted to the AMF in-
creased their death rate (about 35% cell death). More recently, Shanta
Moorthy et al. have used crow ether triad (CET) molecules as gate-
keepers units for a core-shell magnetic mesoporous silica drug delivery
system [16]. These cap molecules were not only thermo- but also pH-
sensitive, and release experiments showed that even though AMF
(14.3 kA/m, 409 kHz) exposure per sedid not induce drug release, a syn-
ergistic effect between both stimuli led to good release profiles. In vitro
experiments showed that the nanocarrier itself had a concentration-
dependent cytotoxic effect, but when cells were exposed to AMF the
cell death rates were higher for each of the nanocarrier concentrations
tested (from 20 to 100 μg/mL). For instance, at 60 and 80 μg/mL the
cell death observed after the exposition to the AMF increased 20%
when compared with the cells without AMF exposition.
DNA molecules have also been used as cap ligands in MSN-based
drug delivery systems, taking advantage of the inner natural ability of
DNA strands to reversibly hybridize with temperature (see section
about release caused by bond break). Besides, it is also known that the
melting temperature can be tuned by changing the ratio of Cytosine-
Guanine (C-G) bonds. Some representative examples of this strategy
are the ones described by Ruiz Hernádez et al. and Zhu et al. In the
first one, the surface of the silica particles was functionalized with a
single-stranded DNA, while the complementary strand was linked to
the MNPs, so once the particles were loaded with the drug molecules,
hybridization of both DNA strands led to the blocking of the pores and
the external exposition of the MNPs [95]. The second approach was
very similar to the first one but in this case the MNPs (lacking DNA
functionalization) were located inside the silica particles, together
with DOX [94]. The mesoporous particles were surface-modified with
a single-stranded DNA and capped with the complementary DNA
strand. In both systems the drug release was tested by externally
heating the nanocarriers, but not under AMF exposure. However,
these results confirmed that the release of the cargo was due to a tem-
perature increase.
The last example concerning MSN carriers is the one published by
Chen et al., in which the authors designed a drug delivery system
based on MSN carriers loaded with a chemotherapeutic drug, (S)-(+)-Please cite this article as: M. Moros, et al., Triggering antitumoural drug rel
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bonds with monodisperse Fe3O4 particles as capping agents [89]. Re-
lease experiments results demonstrated that a repeated exposure of
the nanocarriers to AMF of different durations (1, 3 and 5 min) led to
different drug release profiles. Furthermore, the authors estimated the
number of MNPs that have been removed from the surface of the sys-
tem by measuring the loss of weight after different AMF times (1 to
5 min). The results indicated that the number of MNPs that were re-
moved from the surface went from 2861 particles in the case of one
minute exposure to 14,943 particles in the case of five minutes. In
vitro experiments showed that the nanocarrier was uptaken by A549
cells and the cell viability decreased significantly after 3 min of AMF ex-
posure only in the case of cells treated with the drug-loaded
nanocarrier.
Apart from the silica mesoporous materials, there are other mate-
rials such as mesoporous iron oxide particles that possess at the same
time a nanocrystalline morphology with mesoporous characteristics
and good magnetic properties required for generating heat when ex-
posed to an AMF (Fig. 12). This type of particles were used by Benyettou
et al. for developing a nanocarrier system consisting of mesoporous γ-
Fe2O3 particles with a pore size of about 8 nm and loaded with DOX
molecules [98]. The surface of the particles was covered with a
thermosensitive block copolymer based on ethylene oxide and propyl-
ene oxide, known as Pluronic® F-108, that has large changes in water
content, rigidity and hydrophobicity at 41 °C with respect to its state
at physiological temperature (37 °C). Release test tube results showed
that this delivery system was also sensitive to changes in pH, resulting
in a very slow release of the DOX content under acidic conditions. On
the contrary, a sudden cargo releasewas achievedwhen the nanocarrier
was submitted to an AMF (26.8 kA/m, 464 kHz) for 10 min under the
same acidic conditions, thus achieving the synergistic effect of both
stimuli. Furthermore, when analysing the efficacy of the nanocarrier
in vitro under exposure to the AMF it was observed that, although
some unspecific DOX release promoted cell death in the absence of
the AMF stimulus, the cell viability decreased considerably when cells
were exposed to the AMF for one hour.
Instead of coating the iron oxide surfacewith the thermo-responsive
polymer, Zhang and co-workers used amesoporous iron oxide nanopar-
ticles whose pores were filled with a mixture of a thermo-sensitive
polymer (1-tetradecanol, PCM), PEG (2000) and the chemotherapeutic
agent (DOX) [99]. The role of PEG in themixture is to decrease the inter-
facial tension between the PCM and water, facilitating the release of
DOX. In fact, the release efficiency was N70% higher in the presence of
PEG. Different PCM:PEG:DOX ratios were tested, and the chosen sample
(PCM:PEG:DOX weight ratio of 160:40:1) was stable and presented a
solid state inwater at 37 °C, becoming soluble at 42 °C. This temperature
range is optimal, as it is equivalent to body temperature. Pores of a di-
ameter of around 2.1 nm could be observed in the iron oxide MNPs by
TEM; the disappearance of the pores in the images of MNPs loaded
with the PCM/PEG/DOXmixture, together with Fourier transform infra-
red spectroscopy (FT-IR) confirmed the loading of the nanosystem. Re-
garding the release, in the absence of an AMF, no DOX leakage was
observed for 8 days at room temperature. This reflects that the drug is
safely contained in the nanostructure when no stimulus is applied.
After those 8 days, the system rapidly achieved 80% of DOX release in
b12 h when exposed to an AMF (200 kHz, 47.8 kA/m).
Another recent approach where no “classical” mesoporous
materials-based nanocarrier was used is the one proposed by Wang
et al. The system developed consisted of a core-shell-shell structure
with a cavity centre of 80 nm where the drug (DOX) is located,
surrounded by a layer of magnetite and an outer layer of mesoporous
carbon [100]. The surface was functionalized with chitosan molecules
that interact both covalently and electrostatically with the mesoporous
carbon layer. Release test tube experiments revealed that this coating
prevents the release of the drug molecules at physiological conditions
after 78 h. Besides, the accumulation of the drug released was recordedease and gene expression bymagnetic hyperthermia, Adv. Drug Deliv.
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release during the first 30 min of AMF and only minimal drug release
during the next 9.5 h. Furthermore, in vitro experiments corroborate
that the drug was released from the nanocarrier only in the presence
of an AMF and a synergistic effect between drug release and the heat
produced by the nanocarrier was achieved.
To date, most of the works published in this particular field were
strongly focused on the design and characterization of new drug deliv-
ery systems. Almost in all of them test tube release experiments were
performed for studying the behaviour of the nanocarrier under different
conditions. Many of them, but not all, carry out preliminary in vitro ex-
periments for assessing the potential cytotoxicity of the materials. This
aspect is of great importance, as undesired and non-specific drug re-
lease could occur if the gatekeepers do not block completely the pores
of thematerial, resulting in a cytotoxic effect in physiological conditions,
as indeed can be seen in someworks [16,98]. Furthermore, someworks
also tested the efficacy of the nanocarriers in vitro in different cell lines
under AMF stimulus. Here it is worth mentioning that the conditions
of the AMF reported in different works are very different. For instance,
the exposure time can vary from 10 s [16] to one hour [98]. In almost
all cases a decrease in cell viability after the AMF treatment is observed,
indicating that different drug delivery systems can be remotely acti-
vated by an AMF.
However, there are also fewworks in which the in vivo effectiveness
of the drug delivery systems is tested. For instance, Guisasola et al. and
Wang et al. used different animalmodels (an allograft or a xenograft tu-
mour model, respectively) to investigate the effectiveness of their drug
delivery systems [100,101]. Themodel used byGuisasola et al. consisted
of a heterotopic allograft tumour model where EL4 cells were subcuta-
neously injected in the flank of the animal. The model used in the
work of Wang et al. was a heterotopic xenograft tumour model where
C6 cells were subcutaneously injected in the flank of inmunodeficient
mice. In both works the drug delivery systems were injected
intratumourally and the animals were subjected to several AMF cycles
(three cycles of 30 min, 105 kHz, and 18 kA/m, and four cycles of
30min of AMF using amagnetic generator 110 V 400 A, respectively, al-
though the AMF parameters between both works cannot be directly
compared because of the different ways of providing the data). Results
showed an inhibition in the tumour growth in the groups of animals
that received the drug-loaded nanocarriers and were submitted to the
AMF. In the case of Guisasola et al. it was observed that 48 h after the
last AMF treatment the volume of the tumour with drug-loaded parti-
cles and AMF exposure was the half than of all the controls groups
that were tested (DOX alone, AMF alone, empty nanocarriers with
AMF, drug loaded nanocarriers without AMF) (Fig. 13). In the experi-
ments carried out by Wang et al. an almost complete regression of the
tumour in the group of mice that receive the complete treatment was
observed in comparison with all the controls groups (AMF alone, drugFig. 13. Experimental design and statistical analysis of the differences in tumour volume inmice
withMNP+doxorubicin (MNP@DOX)withoutAMF, groupwithMNP@DOXand exposed to AM
to AMF. Four mice composed each group. Reprinted with permission from ACS Appl. Mater. Inte
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However, a direct comparison of the results obtained in the two studies
is not straightforward, as there were substantial differences in the ex-
perimental procedures.
2.4. Caused by matrix degradation
As a proof of concept, it has been recently reported the possibility to
design thermo-responsive nanostructures that are able to disintegrate
and release molecules upon thermal triggering. Self-immolative poly-
mers (SIPs) consisting in poly(ethyl glyoxylate) (PEtG) can be triggered
to degrade upon the cleavage of a temperature-responsive end-cap
based on a rDA reaction (PEtG-DA) and subsequent furan elimination
[102]. To test the thermo-responsiveness, the polymer was heated at
different temperatures for 24 h, finding that 85% depolymerization oc-
curred at 75 °C, whereas a non-responsive PEtG end-capped underwent
b10% degradation. Thermo-responsive micelles were formed using
DEtG-DA and PEG, and then MNPs were incorporated and the whole
system was subjected to an AMF for 3 h (10.2 kA/m, 755 kHz).
Thermo-induced disassembly of the micelles was demonstrated but
only when AMF was performed at a global temperature of 72 °C; thus
the translation of such nanostructures into the clinical setting is still
very challenging.
3. In situ expression of therapeutic genes
The main objective of gene therapy is the delivery of foreign genetic
material (gene, gene segments or oligonucleotides) into specific cells,
with the main aim to treat or alleviate a disease [103]. In the case of tu-
mours, this approach can be used to inactivate oncogenes, replace de-
fective tumour suppressor genes, or more recently to transfer
transgenes into cancer cells in order to restore normal function or assist
in their death [104].
The possibility of controlling target gene expression in tumours
in vivo in a spatiotemporal fashion is a promising strategy for gene ther-
apy. An emergingway to remotely control gene therapy is based on the
use of magnetic fields, as they can deeply penetrate into tissues [105].
Further, inducible promoters allow the expression of therapeutic
genes in a controllable way. Triggering activation of genes by magnetic
hyperthermia can be approached by using expression vectors contain-
ing heat-responsive promoters [106,107]. The gene products can di-
rectly kill the cells or act in a synergic way to increase the
antitumoural effect of the hyperthermia. One of the first examples of
gene therapy mediated by magnetic hyperthermia was described by
Ito et al. in 2001 [108]. They reported the use of a combined TNF-α
gene therapy driven by the heat-inducible promoter GADD 153
(Growth Arrest and DNA Damage) using magnetite cationic liposomes
(MCLs). After injecting the MCLs with the plasmid containing theafter the different treatments: Control groupwithout AMF, control groupwith AMF, group
F, group injectedwith free doxorubicin and groupwithMNPwithout doxorubicin exposed
rfaces, 2018, 10 (15), pp 12518–12525. Copyright 2018 American Chemical Society [101].
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applied (30.6 kA/m, 118 kHz) for 30 min and the temperature main-
tained at 46 °C. A 3-fold increase in TNF-α expression was observed in
heated tumours compared to control ones, resulting in a significantly
reduction in the tumour volume.
It is widely known that the major group of proteins expressed upon
heat stress is represented by the HSPs, and that evenmild magnetic hy-
perthermia is capable of giving rise to the expression of HSPs in vitro and
in vivo [109]. Therefore, many inducible vectors for gene therapy activa-
tion usingmagnetic hyperthermia have been constructed using expres-
sion systems under the control of a HSP promoter [110]. For instance,
Tang et al. reported that when injecting Mn\\Zn ferrite nanoparticles
and a vector encoding β-galactosidase (β-gal) driven by a HSP70 pro-
moter, β-gal expression was highly increased after AMF treatment
[111]. Although the vector did not encode for an anticancer molecule,
the feasibility of using these inducible promoters together with mag-
netic hyperthermia was demonstrated. Similarly, Yamaguchi et al. ex-
plored the remote activation of the therapeutic gene TNF-α with MCLs
and AMF using a gene expression system under the control of a
HSP70B’ promoter [112]. Once activated by heat, the HSPs could bind
the promoter, acting as a switch to induce the expression of TNF-α. Ad-
ditionally, a tetracycline (Tet-) transactivator system was included in
the plasmid, as a positive feedback loop to enhance the activity of the
HSP70B’ promoter. In vitro, human lung adenocarcinoma A549 cells
were transfected with the construct, incubated with MCLs and sub-
jected to AMF exposure (30.6 kA/m, 118 kHz) for 30 min. The tempera-
ture was controlled at 43 or 45 °C by adjusting the electrical power, and
the TNF-α production and cell viability were measured. TNF-α produc-
tion in cells transfected with the plasmid was only observed after AMF
exposure, indicating that the HSP70B’ promoter was activated by the
temperature increase triggered by the MCLs under the AMF. Cell viabil-
ity also decreased drastically in cells transfected with the therapeutic
system and exposed to the AMF, when compared with cells transfected
with a mock plasmid or not exposed to the AMF. In vivo, heat-induced
TNF-α gene therapy was evaluated in mice bearing tumour xenografts.
Onlywhen the therapeutic genewas present and the animals were sub-
jected to the AMF for 30min, the tumour volume diminished and a high
concentration of TNF-α was found in them. In order to avoid the
intratumoural injection and/or to overcome the limited tumour
targeting ability of conventional carriers, Yin et al. proposed the use of
mesenchymal stem cells (MSCs) to deliver the vector [113], as MSCs
possess the intrinsic ability tomigrate to tumours. The systemwas com-
posed of magnetic zinc-doped iron oxide NPs coated with a silica shell
(MCNP), complexed with a heat- inducible gene vector (HSP70B’ pro-
moter) encoding a secretable formof TNF-related apoptosis-inducing li-
gand (Fig. 14A-D). TRAIL is amember of the TNF superfamily, which can
selectively induce apoptosis through an extrinsic pathway in a broad
range of human cancer cells, while sparing normal cells. Targeting the
extrinsic pathway is considered a promising strategy to regulate apo-
ptotic cell death when compared to the intrinsic one, as the later fre-
quently gives rise to drug resistance [114]. Despite the encouraging
preclinical results, its clinical translation has been limited due to its
short biological half-life in vivo [115]. To overcome this limitation, the
proposed MNPs had the dual purpose of enhancing the delivery of the
heat-inducible plasmid to theMSCs bymagnetic uptake, and of activat-
ing the production of TRAIL via mild magnetic hyperthermia. Hence,
once the MNPs bearing the vector were loaded into the MSCs, these
MSCs carrying the MNPs along with the vector were exposed to an
AMF for 1 h (5 kA/m, 225 kHz), achieving a temperature of 41 °C. To cor-
roborate that TRAIL was being secreted, this conditioned media from
MSCs exposed to the hyperthermia was collected and added to ovarian
cancer cells A2780 in vitro (Fig. 14 E). An important decrease in cell vi-
ability was found when compared to cells treated with conditioned
media of MSCs not exposed to the AMF (Fig. 14 F). The activation of
caspases, which are implied in apoptosis cell death, was demonstrated
by qPCR (quantitative Polymerase Chain Reaction) (Fig. 14 G).Please cite this article as: M. Moros, et al., Triggering antitumoural drug rel
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utilizes exogenous enzymes for the controlled conversion of prodrugs
to drugs only in target cells. To this end, Nemani et al. proposed the
use of alginate microcapsules containing MNPs and an engineered
E. coli strain expressing cytosine deaminase upon thermal induction
[116]. In this sense, E. coliwasdesigned to overexpress the enzyme at el-
evated temperatures (42 °C) when compared to 30 °C, by ligating the
cytosine deaminase gene under the transcriptional control of a
thermo-responsive promoter cassette. Once expressed, this enzyme is
able to convert the non-toxic prodrug 5-fluorocytosine (5-FC) to the
toxic metabolite 5-fluorouracil (5-FU), which inhibits cell proliferation
leading to cell death [117]. After encapsulating these modified E. coli
bacteria with iron oxide nanoparticles in alginate capsules, the applica-
tion of an AMF (35.9 kA/m, 30 min) led to remote triggering of cytosine
deaminase expression. As a proof of concept, three tumoural cell lines
were incubated with the microcapsules already pre-heated at 42–43
°C using an external water bath or an AMF, together with the prodrug
for 72 h, and the cell viability evaluated. The cytotoxicity of the micro-
capsules activated by AMFwas comparable to that of the microcapsules
pre-heated in a bath, and to the one produced by 5-FU by its own. On
the other hand, the microcapsules without the prodrug also showed
toxicity, which could be related to the presence of bacterial toxins. Al-
though the magnetic triggering of cytosine deaminase expression was
demonstrated, further studies should be performed to demonstrate
the feasibility of the system once incorporated into cells.
4. Conclusions and future remarks
Thermo-responsive nanocarriers based on magnetic nanoparticles
have remarkable potential for applications in cancer treatment. Recent
developments in the synthesis and functionalization of nanoparticles
led to the creation of a large toolbox for engineering the physico-
chemical features of the nanocarrier that enable the on-demand release
of therapeutic drugs under the magnetic hyperthermia stimulus, with
excellent spatiotemporal control. As highlighted in the first section of
this review, drug release from thermo-responsive matrices can be
achieved by a multitude of strategies, including bond breaking, matrix
transformation or degradation, and the use of switchable gates. The
use of MNPs also capitalizes on the synergistic effect of the combined
magnetic hyperthermia – chemotherapy approach to enhance the treat-
ment efficiency. Moreover, multifunctional nanocarriers can be de-
signed, by introducing tumour-targeting ligands to improve their
targeting capability, or specific fluorescent dyes to enablemolecular im-
aging. By engineering the formulation of the nanocarrier, it is also pos-
sible to obtain platforms for asynchronous delivery of two different
chemotherapeutics (which opens up new avenues for addressing mul-
tidrug resistance in cancer treatment), or to create dual stimuli-
responsive nanocarriers.Magnetic hyperthermia has also demonstrated
its potential as a promising strategy for controlling in situ expression of
therapeutic genes or enzyme-mediated conversion of anticancer
prodrugs into drugs.
Despite tremendous advances regarding the design and characteri-
zation of the nanocarriers, the numerous proof of concept examples at
test tube and in vitro level, and some promising in vivo results, the
field still faces several important challenges. For instance, the heat gen-
erated by the MNPs alonemust be always carefully assessed in order to
establish its role in the cellular death. In several of the examples
discussed in this review it has been shown that sometimes MNPs
alone are able to induce a high extent of cellular damage,while in others
the cell death could not be unequivocally attributed to the released che-
motherapeutics, as no sufficient data on the effect of the MNP heating
alone were provided. Special attention must be also paid to the melting
temperatures of the thermo-sensitive molecules used in the design of
the nanocarriers for in vivo applications. On the one hand the premature
release of the drug at physiological temperature must be avoided, while
on the other hand the release should take place at clinically relevantease and gene expression bymagnetic hyperthermia, Adv. Drug Deliv.
Fig. 14.MildMagnetic Hyperthermia-Activated Stem Cell-Based Gene Therapy. A)MCNPs (magnetic core-shell nanoparticles) composed of a ZnFe2O4 MNP core and a mesoporous silica
(mSi) shell (i) are functionalized with PEI to allow for complexing with a heat-inducible therapeutic plasmid (iii). The MCNPs enhance delivery of the heat-inducible plasmid into the
adipose-derived mesenchymal stem cells (AD-MSCs) via magnetically- facilitated uptake (iv–v). These engineered ADMSCs can then be injected in vivo (vi), where they innately home
to the tumours/metastases. Finally, mild magnetic hyperthermia, via exposure of the MCNPs to an AMF, can be used to specifically activate the heat-inducible secretion of therapeutic
TRAIL from the AD-MSCs (vii). B) The heat-inducible plasmid is composed of a HSP70B’ promoter and a secreted form of TRAIL (sTRAIL) that is fused to an EGFP (enhanced green
florescent protein) reporter. C) TEM image of the MCNPs. D) Schematic depicting the sTRAIL-EGFP plasmid (i), which expresses a sTRAIL-EGFP fusion that is constitutively activate,
and the HSP-sTRAIL plasmid (ii), which expresses the same sTRAIL-EGFP fusion under the control of a heat-inducible HSP70B’ promoter. E) Timeline of the in vitro study. F) To test
therapeutic efficacy, A2780 ovarian cancer cells were treated with conditioned media from the engineered AD-MSCs that were exposed to mild MHT. A2780 cells showed a
remarkable decrease in cell viability when compared to those treated with conditioned media from engineered AD-MSCs that had not been exposed to AMF. G) To confirm the
mechanism of action, qPCR for caspases, which are downstream of TRAIL, was performed. Adapted from [Stem cell-based gene therapy activated using magnetic hyperthermia to
enhance the treatment of cancer] Licensed Content Publisher JohnWiley and Sons. [113].
15M. Moros et al. / Advanced Drug Delivery Reviews xxx (xxxx) xxx–xxxhyperthermia values (41–44 °C). Another major problem that renders
the comparison of results obtained by different groups practically im-
possible is related to the parameters used for magnetic hyperthermia
experiments (in terms ofmagnetic field amplitude and frequency, dura-
tion of application of the AMF, number of applications). Another prob-
lem is the low drug loading achieved in some cases, which may not be
enough to achieve a successful treatment. Finally, given the complexityPlease cite this article as: M. Moros, et al., Triggering antitumoural drug rel
Rev. (2018), https://doi.org/10.1016/j.addr.2018.10.004of cancer, it is also complicated to compare results from research works
using different tumour cell lines.
As a final critical reflection, we believe that due to their rather large
structural complexity the nanocarriers described in this review are at
themoment in their very incipient stages of clinical development. How-
ever, we think that the field of thermo-responsive nanomaterials will
continue to be a very prolific research area in the coming years andease and gene expression bymagnetic hyperthermia, Adv. Drug Deliv.
16 M. Moros et al. / Advanced Drug Delivery Reviews xxx (xxxx) xxx–xxxwe are confident that by addressing all the afore mentioned challenges,
the next generations of heat-responsive nanoplatforms could provide
new solutions for cancer treatment.
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